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Michael C. Flickinger is Associate Professor of Biochemistry and Director of the Institute 
for Advanced Studies in Biological Process Technology at the University of Minnesota. 
Minnesota's Strengths 
The biotechnology industry in Minnesota can be broadly 
defined as including biomedical device firms, biological 
engineering firms, industries that produce research or manu-
facturing equipment for biotechnology or treatment of pro-
cess wastes, and industries that provide fermentation sub-
strates. This definition of biotechnology-related industries is 
significantly different than in other states where the focus of 
biotechnology-related research and development is primarily 
in major pharmaceutical and chemical manufacturing firms. 
In general, Minnesota has a strong entrepreneurial empha-
sis for promoting new industries, relatively low unemploy-
ment, and an excellent educational system. However, Minne-
sota has not recognized the potential for positive economic 
development, specifically for attracting new firms related to 
biotechnology, as have many other states. Over the last four 
years, states such as North Carolina, Delaware, New Jersey, 
Colorado, Michigan, Massachusetts, Maryland, Pennsylvania, 
Tennessee, Virginia, New York, and California have encour-
aged biotechnology by marketing their states' educational, 
business, and high technology resources to investors and 
entrepreneurs. These states have specifically sought to attract 
biotechnology firms and to coordinate research in progress in 
academic institutions, the private sector, and at federal labora-
tories located within their states. Particularly good examples 
of effective promotional information are the publication 
"Techne" by the North Carolina Biotechnology Center ancf the 
Colorado Bio-Industrial]ournal ( 1 ) , which recently reported 
on the number ofbio-industrial companies founded in Colo-
rado since 1968 (Figure 1). 
Minnesota has only recently developed similar compre-
hensive plans for attracting biotechnology industries. In 1985 
the Governor created a task force to decide on the most 
appropriate direction for educational and business develop-
ment to attract biotechnology-related industry to Minnesota 
(2 ). From this task force report, a state Biotechnology Council 
was formed, led by industry and higher education, which has 
recently published an extensive plan for biotechnology 
development ( 3). One key component of this plan is a survey 
of the potential economic impact of biotechnology on the 
state ( 4 ). This recent economic analysis projects that 20,000 to 
68,000 new jobs could occur as the result of development of 
new industries in biotechnology by the year 2000 (Figure 2 ). 
These projections may be conservative. The basis for this 
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projection included 100 established firms in Minnesota 
related to biotechnology, with a current employment of9,000 
individuals (Table 1 ). The analysis did not include expansion 
of existing significant biotechnology research groups in 
related industries. 
Table 1. Calculation of Minnesota 1985 "base-year" employment in 
the biotechnology industry ( 4). 
Biomedical Biological 
Devices Engineering 
Number of Firms 
Meeting Definition 83 11 
Number for which Employment 
Was Found 69 8 
Identified Employment 8,424 308 
Firms for which Employment 
Figures Missing 14 3 
Values Used Per Firm for 
Missing Employment Figures 15 10 
Additional Employment Assumed 210 30 
Total Employees (subtotal 
plus additional) 8,634 338 
Figure Used for Projection 
(rounded) 8,650 350 
The major components of Minnesota's strength in biotech-
nology development are the breadth and quality of the Uni-
versity of Minnesota biological, engineering, biomedical, 
agricultural, and dairy research programs, which rank among 
the highest in the nation in terms of funded research (5). 
These programs have been augmented by a baccalaureate 
biotechnology interdisciplinary degree program in the State 
Universiry system, which includes a program for introducing 
high school science teachers to basic methods in biotechnol-
ogy (3). 
Major Constraints 
Even though a statewide plan developed by industry, state 
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Figure 1. Biotechnology company foundings and employment in 
Colorado since 1968 (1 ). 
constraints must be overcome if development of a more active 
biotechnology-related state industry is to occur. These con-
straints are 1) ineffective two-way communication between 
faculty associated with basic research and scientists in firms 
interested in applications ofthese results ; and 2) the present 
minimal coordination among faculty and among academic 
institutions resulting in duplication of research and educa-
tional programs. 
A variety of techniques exist for the transfer of genes into 
appropriate vectors and host organisms for expression and 
subsequent scale-up to manufacture of large quantities of 
diagnostic or therapeutic proteins, drugs, enzymes, and bio-
polymers for industry. Much of this technology is poorly 
protected by traditional process patent or new-composition-
of-matter patent law. Consequently, for competing firms to 
maintain a competitive technology, research and develop-
ment must remain trade secrets. This results in major com-
munication restraints between industries and between indus· 
try and academic laboratories unless specific proprietary 
agreements are negotiated with each faculty laboratory to 
limit the dissemination of research results prior to publication 
or patent disclosure. 
Communication 
Communication problems in three areas exist that have in 
the past constrained development of new industries created 
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from basic research in academic institutions: university-
university communication, university-industry communica-
tion, and the developing industries' ability to effectively 
communicate with state government. Ifbiotechnology specif-
ically is to be fostered, then these communication constraints 
need to be considered carefully before major decisions or 
programs are created. 
Widely promoted is the concept of technology transfer 
between the university community and industry. However, 
before questioning whether this can be fostered, it is impor-
tant to consider communication among faculty at the same 
academic institution and between academic institutions . 
Past experience indicates that communication among 
faculty at the same institution is often less than optimal. The 
organization and coordination offacultywithin a discipline is 
often difficult-much less between disciplinary areas. Com-
munication between academic institutions is hindered and 
actually discouraged due to the traditional mechanisms of 
competitive grant support from federal or industrial sources. 
With respect to biotechnology as a specific new industry 
and the proprietary constraints dictated by current patent law, 
additional professional and ethical guidelines often need to 
be developed to insure separation of academic and business 
interests for faculty that teach and supervise students while 
consulting or actively participating in the creation of new 
start-up industries. This question of limited communication 
between industry researchers and academic scientists has 
often been debated with regard to the potential negative 
effects it may have through limiting academic freedom. 
Recent evidence suggests that funding of academic research 
by industry over the past two decades has not resulted in 
significant compromises of the freedom of the researchers to 
train students and publish their results ( 6). 
Academic faculty in related fields can interact with industry 
by a variety of mechanisms: on a one-to-one basis or as groups 
of faculty in a cooperative or consortium agreement (Table 2 ). 




























-not long lasting 
-cannot maintain 
proprietary position 
The one-to-one relationship between faculty and industry 
will always exist. This is a rapid way for industry to address 
specific questions. It can be done efficiently by faculty giving 
seminars or conferences, and faculty acting as individual con-
sultants. Proprietary interests can be maintained because the 
relationship is limited in scope. This type of interaction, how-
ever, involves a limited number of participants, is not generic, 
and usually does not lead to development of major new 
industries. 
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Figure 2. Projected Minnesota employment in the biotechnology industry. ( 4). 
Coordination 
Cooperative agreements among faculty and with more than 
one industty are being actively fostered by federal research 
programs such as the Industty/University Cooperative Re-
search Centers program of the National Science Foundation 
(NSF) (Table 3) (6). This program has created national Gen-
ters for consortia of companies and large numbers of partici-
pating faculty. These types of interactions differ from the 
one-on-one faculty-industty interactions in that a large 
number of faculty are involved and more than one industty is 
participating. Firms in this program may sponsor research that 
crosses disciplinaty lines and involves faculty from a variety of 
traditional academic departments. The participating firms may 
have the opportunity to negotiate with the university for 
reduction in indirect costs, licensing, acquisition of particular 
technologies and patenting of research results in order to 
create incentives for sponsoring research in an academic 
environment as opposed to within their own firms. There may 
also be sharing of personnel and facilities between the univer-
sity and participating industries in these centers or consortia. 
The students participating in these activities may obtain bene-
ficial exposure to the significant problems in the participating 
industries or even work in industrial research laboratories as 
part of their educational experience. 
Volume 53, Number 1, 1987/88 
Table 3. The role of university/industry consortia in biotechnology 
development. 
• Forum for exchange 
• Collaborative projects 
• Provides industry-industry exchange 
• Two-way internships 
-personnel 
-lectures, seminars, courses 
-facility sharing 
• Industrial advisory roles 
• Leveraged R&D expenditures 
• Right of first refusal 
• Recruitment 
• Faculty insights to industry 
• "Beta" site at university 
In biotechnology-related disciplines, however, these re-
search consortia are difficult to foster because of the proprie-
taty nature of the research. Consortia by definition have to 
pool resources to address common or generic questions to 
the benefit to all sponsoring organizations. This significantly 
leverages each participating firm's investment as well as min-
imizes the risks. Because of the mechanism of pooling of 
resources, however, it is less likely that this type of research 
will be related to a specific product for a specific firm. 
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It is unfortunate that among the 39 NSF centers specifically 
designed to foster industry/ university cooperative research, 
only two directly related to biotechnology have been sup-
ported by industry. These are the Monoclonal Antibody Lym-
phocyte Engineering Research Center in North Carolina and 
the Center for Biocatalytic Processing in Minnesota. 
In addition to the Industry / University Cooperative Research 
Programs, the NSF has also created Engineering Research 
Centers (ERCs) as an additional mechanism to develop 
university-industry collaborative consortia (6). One ERC 
directly related to biotechnology is the Massachusetts Institute 
ofTechnology's Engineering Research Center in Biochemical 
Process Engineering, which has a five-year, $20 million grant 
from NSF with active financial participation from biotech-
nology-related industries. In this case, a major commitment 
was required by the academic institution in terms of space, 
administrative staff, industrial liaison staff, and patent office 
staff to coordinate the center. The annual operating overhead 
expenditure for the administration of this large corsortia is 
$200,000-$300,000. This cost does not include the space 
required by visiting industrial scientists and new equipment 
specifically for the center use. Nor does this figure reflect the 
amount of time required by the faculty involved, not only for 
the research but to effectively interact with the large number 
of participating firms by presenting research reports at annual 
center meetings, entertaining visiting scientists from industry, 
and acting as individual consultants to the member firms. 
The commitment of faculty time is, in many cases, the 
greatest restraint. These collaborative and consortia activities 
compete with faculty teaching time and the time required for 
faculty to effectively recruit and train graduate students. 
Faculty members continue, as they always have in the past, to 
be primarily interested in scholarly publication and teaching, 
which lead to their ability to attain tenure and be promoted. 
Unless academic-industrial interactions are recognized and 
fostered by the promotion and tenure process, as they are at a 
small number of technological institutions in this country and 
more extensively in foreign countries, there will continue to 
be little incentive for many faculty to participate in view of 
their other time commitments. 
Some institutions have created centers or industries known 
as organized research units ( ORUs) to address these interdis-
ciplinary administrative, space, and time commitment prob-
lems (7). In some instances, collaboration has been fostered 
by releasing faculty from teaching and university service 
responsibilities. If not monitored closely by the institution, 
this may contribute to inequities among faculty and further 
discourage faculty participation. 
Creation of Incentives 
Many firms in advanced technologies have traditionally 
sought to leverage their abilities by locating themselves near 
academic institutions. The objective is to foster translation of 
developing technologies from an academic, basic research 
environment into the developing new industry. 
Implicit in this assumption is that there are few communica-
tion constraints between the academic and private sector 
institutions. How realistic is this assumption for biotechnol-
ogy and should Minnesota emphasize this similar approach 
for development of new biotechnology industries? 
State Promotion 
Many states are seeking to promote biotechnology-related 
industries in spite of the proprietary nature ofthis technology 
by promoting evidence of existing collaborations between 
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academic and private researchers. The state of Texas, for 
example, has structured an approach where the major fraction 
of biotechnology-related new research funds could come 
from the private sector through the Dallas Biotechnology 
Development Corp. (8). Other states have created similar 
mechanisms, primarily using private or state funds derived 
from a major existing state industry to attempt to stimulate 
translation of biotechnology research into industrial results. 
Some states have chosen to foster communication by crea-
tion of industrial parks specifically tailored in their design and 
facilities for biotechnology industry. One example of this is 
the Massachusetts Biotechnology Research Park (9) , which is 
located adjacent to 10 educational institutions with specific 
business incubator facilities for biotechnology-related indus-
try. Table 4 summarizes the time lag from creation of the 
Worcester Biotechnology Development Corp. (WBDC) to the 
actual beginning of construction of facilities (9). This exam-
ple. emphasizes the legislative milestones, enabling legisla-
tion, tax incentives, and zoning, which had to be created prior 
to actually building and attracting tenants. 
Table 4. Milestones in the development of the Massachusetts Bio-
technology Research Park. (MBRP) 
• WBDC First to Propose a Biotechnology Com-
plex on 75 acres on Plantation Street in Wor-
cester 
• Land Declared Surplus by the Board of Trus-
tees of the University of Massachusetts 
• Deadline for Developers' Proposals for Use of 
Plantation Street Land 
• WBDC Awarded Development of Park by 
Governor Michael S. Dukakis 
• Enabling Legislation Passed 
• Scientific Director Appointed 
• Cooperation Between the WBDCand the Uni-
versity of Massachusetts Medical Center 
Established 
• Sasaki Associates Selected as the Design Firm 
• Environmental Impact Report Process 
Initiated 
• Massachusetts Biotechnology Research Insti-
tute Incorporated 
• Title to Land Conveyed by State 
• City Zoning Ordinance Approved 
• City Biomedical Research Ordinance 
Approved 
• Title Insurance Obtained 
• Project Director Appointed 
• Bill Creating Center of Excellence in Biotech 
Park Signed by Governor 
• Final Environmental Impact Report Certified 
by Massachusetts Secretary of Environmen-
tal Affairs 



















Recently, the city of Minneapolis and the University of 
Minnesota have rekindled development of a similar high 
technology park to be located next to the University as a 
potential lure to attract new high technology industry (10). 
Current tenants in this development include the University's 
Supercomputer Institute and firms that will benefit from 
access to this facility. In the future , however, this development 
could also be tailored to attract biotechnology-related indus-
tries. A similar 110-acre Minnesota Medical Enterprise Park 
devoted exclusively to medical technology is being deve-
loped in Coon Rapids (11). 
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Industry- University Communication 
Physical proximity of these developing industries to aca-
demic institutions alone, however, does not insure effective 
communication between academic and industrial researchers. 
Effective avenues of communication in Minnesota need to 
be opened so that industry-university communication is not a 
one-way street. Developing industries seeking collaborations 
with academic scientists require mechanisms not only to find 
faculty involved in related basic research but also to protect 
disclosure of their needs and plans. This is the primary prob-
lem in development of a biotechnology industry-complete 
disclosure is seldom possible due to the proprietary nature of 
the developing technology. 
The fostering of industry-university communication could 
also be stimulated by distribution to industry of information 
concerning faculty research interests and expertise. Where 
does a new company go when it wants to find this basic 
information? Simply listing faculty research interests will not 
indicate to firms which faculty have any interest in or percep-
tion of the significant technological hurdles for development 
of new industries. 
Overcoming Constraints in Minnesota 
Table 5 summarizes the active participation required by 
industry, state government, and academic institutions in order 
to overcome communication and coordination constraints 
and enhance university-industry interactions in Minnesota in 
biotechnology. Primary considerations must be to coordinate 
efforts among academic institutions, avoid duplication, and at 
the same time promote communication between industrial 
and academic scientists (Table 6). 
Table 5. Commitments needed by state industry and government to 
foster biotechnology development. 
• Industry must demand active participation and financial sup-
port from state government for: 
1. Training programs for workforce 
2. Long term high quality research and facilities for 
research 
3. Mechanisms to reward participation by faculty in both 
basic and applied research 
• Industry must work with State government to revise the busi-
ness climate for both biotechnology start-ups and expan-
sions. 
• Government and industry must promote Minnesota as a 
coordinated biotechnology climate with existing educational 
progrnms. • 
Effective and equitable mechanisms must be explored to 
reward faculty for participation in research and industrial 
collaborations to foster state industry. This reward mechanism 
must be factored into the regular promotion and tenure pro-
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Table 6. Methods to enhance university-industry interactions in 
Minnesota. 
• Develop university, private colleges, AVTI consortia 
- Sharing of personnel, facilities, students 
• Method of faculty reward for participation 
- Contribution to tenure, promotion decisions 
- High standard of quality in both research and teaching 
• Clear definition to state industry of educational resources 
- What talent exists and where 
-Specific interests of individual universities 
- Geographic distribution within the state 
cess in such a way to sustain only the highest standard of 
teaching and research. The experience of other states has 
shown that in order to foster new industry, academic institu-
tions must contribute the highest quality and most innovative 
research and teaching programs, which can be coordinated 
with a business environment that promotes rapid develop-
ment and translation of the results of basic research into new 
ventures. 
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